This research finding should benefit the company’s Colaris test, which identifies genetic mutations in the MLH1, MSH2, MSH6, and PMS2 genes and assesses a person's risk of developing colorectal and ...
First-mover advantage is no guarantee of early success. Myriad Genetics, which makes diagnostic tests to detect predisposition to cancers, burned through more than $500 million over 17 years before ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback